The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.
 
Daniel H. Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Bassam Bassam Sonbol
No Relationships to Disclose
 
Donald Wender
No Relationships to Disclose
 
Kelsey Klute
Consulting or Advisory Role - Cancer Expert Now; Daiichi Sankyo/Lilly; Pfizer
Research Funding - AstraZeneca (Inst); FibroGen (Inst)
 
Zhaohui Jin
No Relationships to Disclose
 
Jeremy Clifton Jones
No Relationships to Disclose
 
Angela Ulrich
No Relationships to Disclose
 
Blake Waechter
No Relationships to Disclose
 
Heather Young
No Relationships to Disclose
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Rafael Pharmaceuticals
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; HalioDx
Speakers' Bureau - AstraZeneca; Bayer; Diiachi Sankyo; HalioDx; Lilly; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Ipsen (Inst); Isofol Medical (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Caris Life Sciences
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
John H. Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera (Inst); Pfizer; Roche/Genentech (Inst); Seagen; Silverback Therapeutics; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Exelixis (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network